Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

BACKGROUND: Although immune checkpoint inhibitors (ICIs) have influenced the treatment paradigm for multiple solid tumors, increasing evidence suggests that primary and adaptive resistance may limit the long-term efficacy of ICIs. New therapeutic strategies with other drug combinations are hence war...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pei, Du, Yang, Bai, Hua, Wang, Zhijie, Duan, Jianchun, Wang, Xin, Zhong, Jia, Wan, Rui, Xu, Jiachen, He, Xiran, Wang, Di, Fei, Kailun, Yu, Ruofei, Tian, Jie, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648046/
https://www.ncbi.nlm.nih.gov/pubmed/36352411
http://dx.doi.org/10.1186/s12916-022-02598-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648046/
https://www.ncbi.nlm.nih.gov/pubmed/36352411
http://dx.doi.org/10.1186/s12916-022-02598-5

Ejemplares similares